← Back to Clinical Trials
RecruitingNCT06893861

Assessment of the Effectiveness of the Metabolomic Approach in Screening for Endometrial Cancer

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionEndometrial Carcinoma (EC)
SponsorNational Cancer Institute, Naples
Study TypeOBSERVATIONAL
PhaseN/A
Enrollment3,100
SexFEMALE
Min Age50 Years
Max Age80 Years
Start Date2023-07-06
Completion2025-07
Interventions
Metabolomic profiling

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The study involves the use of reagents or materials for diagnostic assessments that are not commercially available, specifically a metabolomic signature for screening endometrial carcinoma and/or other types of cancers, and follows a case-control design. This study aims to achieve several objectives that contribute to evaluating the diagnostic potential of a specific "metabolomic signature" to be used for screening endometrial carcinoma. Specifically, the study seeks to assess the signature's discriminative ability in differentiating between benign endometrial neoplasms and neoplasms of different histological origins.

Eligibility Criteria

Inclusion Criteria: 1. Female sex 2. Age between 50 and 80 years 3. Willingness to participate in the study and signing of the informed consent 4. Clinical condition of post-menopause Exclusion Criteria: 1. Previous hysterectomy 2. Hormone replacement therapy 3. Immunosuppressive therapy

Related Trials